Condition
Phosphomannomutase 2 Deficiency
Total Trials
5
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Completed2
Terminated1
Active Not Recruiting1
Enrolling By Invitation1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06657859Phase 2Enrolling By Invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT03173300CompletedPrimary
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
NCT06892288Phase 2Active Not RecruitingPrimary
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
NCT05549219Phase 2Completed
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
NCT04925960Phase 3Terminated
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Showing all 5 trials